Background: Evidence is accumulating to suggest that clinical guidelines should be modified for patients with comorbidities, yet there is no quantitative and objective approach that considers benefits together with risks.
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VIDENCE IS ACCUMULATING TO
suggest that some clinical guidelines should be modified for patients with severe comorbidities. [1] [2] [3] [4] [5] Patients with comorbid illness have higher competing risks of death and therefore may be unlikely to survive long enough to benefit from disease-specific guidelines that have delayed benefits but immediate harms. 2, 3 For example, it seems unwise to recommend colorectal cancer screening for a woman with severe congestive heart failure (CHF) because she may die before the benefits from colonoscopy outweigh the harms. Data supporting clinical guidelines usually exclude patients with substantial comorbidity burdens and therefore do not suggest how guidelines should be individualized for patients with comorbidities that substantially affect life expectancy. [1] [2] [3] 5 Although providers have the option of using clinical judgment to withhold interventions when harm is likely to exceed benefit, a substantial body of evidence suggests that providers do not make this assessment accurately. In a study of nearly 600 000 veterans in care, 33% of very elderly patients (aged Ն85 years) were screened for prostate cancer, even though few of them were likely to survive until the benefits of screening could exceed the harms. 6 Also, those who had multiple chronic illnesses were screened as often as those who were well. Among patients in whom early-stage colorectal cancer was detected by screening, many had 3 or more chronic conditions and did not survive long enough to benefit from the early diagnosis. 7 The advent of incentives and reinforcement mechanisms (eg, pay for performance, quality "benchmarks," and rudimentary clinical reminder systems) will likely reinforce inclinations to apply guidelines rigidly. 4, 8 Approaches have been advocated for tailoring guidelines based on the scope and severity of comorbidities. [1] [2] [3] [4] [5] However, these approaches may be difficult to apply at the point of care because they do not weigh benefits and harms quantitatively and therefore may not offer concise and transparent support for clinical decision making. We investigated whether we could develop a framework for individualizing guidelines that was simple enough to be used within a clinical decision aid at the point of care, yet was complex enough to weigh harms and benefits quantitatively. To illustrate our framework, we focus on 1 particular guideline (colorectal cancer screening) and 2 common comorbidities (human immunodeficiency [HIV] and CHF); however, our approach can be applied broadly to other guidelines and other chronic diseases.
METHODS
Our framework is based on the observation that potential benefits from guidelines often occur subsequent to potential harms. If a particular patient is unlikely to survive until the cumulative benefits from a guideline exceed its cumulative harms, the guideline is unlikely to help that patient. [1] [2] [3] We define benefits as any outcomes that lessen morbidity and/or mortality, and these outcomes are generally the desired consequences of a guideline (eg, risk reduction of adverse outcomes such as colorectal cancer incidence). We define harms as any outcomes that increase morbidity and/or mortality, and these outcomes are generally the undesired consequences of a guideline (eg, side effects or complications such as perforation of the colon).
We define payoff time as the minimum time until the cumulative incremental benefits that are attributable to a guideline exceed its cumulative incremental harms. When the payoff time of a guideline is longer than a patient's estimated life expectancy, then that guideline is unlikely to benefit that patient. The concept of a payoff time is applicable to any clinical guideline for which the expected harms occur over a shorter time horizon than the expected benefits. For example, using colonoscopy to screen for colorectal cancer is likely to have a payoff time because its harms (eg, chance of colon perforation or discomfort) occur quickly, at the time of the procedure, whereas its benefit (eg, decreased mortality risk from colon cancer) occur later, over a longer period of time. In contrast, other guidelines (eg, lipid-lowering treatment) may not have payoff times because their harms (adverse effects and inconvenience of medications) occur more contemporaneously with their benefits (decreased risk of cardiovascular events) or because their benefits never exceed their harms. It is rarely possible to identify every possible benefit and harm; therefore, only those benefits and harms that are of particular importance are likely to be considered in payoff time calculations. For payoff times to be clinically meaningful, benefits and harms should encompass events of comparable clinical impact, much like composite end points in clinical trials.
The comorbid populations that we chose to illustrate our approach were 50-year-old men with chronic HIV infection and 60-year-old women with CHF, and the clinical guideline that we chose to evaluate was colorectal cancer screening. Colorectal cancer screening may take a variety of forms. For this analysis, we decided to evaluate screening colonoscopy once every 10 years. We calculated payoff times based on 2 specifications of benefits and harms: the first includes only effects on mortality (mortality payoff time), and the second includes only effects on serious clinical events (adverse event payoff time).
CALCULATING THE PAYOFF TIME
We calculated the payoff time by determining when the cumulative incremental benefit of the guideline first becomes larger than the cumulative incremental harm. Correspondingly, the mortality payoff time for colorectal cancer screening occurs when the cumulative mortality decrease from fatal colorectal cancers first becomes larger than the cumulative mortality increase from fatal complications (eg, fatal perforation of the colon). Similarly, the adverse event payoff time for colorectal cancer screening occurs when the cumulative risk reduction of colorectal cancer incidence first becomes larger than the cumulative risk increase from serious complications (eg, perforation of the colon).
In this report, we estimate payoff times based on mortality and significant adverse events; however, it should be noted that payoff times may also be formulated using alternative specifications for outcomes (eg, considering decrements in quality as well as quantity of life), in which case they may take into consideration other consequences, including the discomfort associated with screening.
DATA SOURCES Estimating the Payoff Time
We estimated age-and sex-specific colorectal cancer incidence and death rates from SEER (Surveillance, Epidemiology, and End Results) surveillance data (2000) (2001) (2002) (2003) . 9 Because we sought to design a framework that could be linked to existing clinical guidelines, we based our analysis on the same data sources that were used by expert panels to formulate guidelines. In particular, we estimated the risk reduction for colorectal cancer based on those data sources used by the US Preventive Task Force to construct colorectal cancer screening guidelines. 10 Because these studies [11] [12] [13] [14] [15] [16] [17] did not agree on the magnitude of risk reduction (range, 49%-90%), we used an intermediate estimate (70%) for this analysis.
Similarly, we estimated the likelihood of colon perforation and the likelihood of death from colon perforation based on the data sources used by the US Preventive Task Force.
11 -17 Because we were applying these data to populations with significant comorbidites, we selected upper bound risk estimates from among the ranges reported in these studies (risk of colon perforation per colonoscopy, 0.20%; range, 0.07%-0.20%; risk of death from colon perforation, 0.020% per colonoscopy; range, 0.005%-0.024%).
Estimating Life Expectancy
Estimating comorbidity-specific life expectancy may be accomplished by a multitude of methods, including natural history models of particular diseases, estimations by the "declining exponential approximation of life expectancy" (DEALE), 18 or approximation based on age and quartile of relative health. 3 For the patient groups that are the focus of this report, we estimated the life expectancy for patients with HIV based on the mechanistic model of HIV progression developed by Braithwaite et al, [19] [20] [21] which predicts survival and time to failure of antiretroviral regimens based on patient characteristics including age, CD4 lymphocyte count, and viral load; and we made inferences regarding the life expectancy for patients with CHF based on the Seattle Heart Failure Model, 22 which predicts survival over a 3-year period based on a wide spectrum of patient and treatment characteristics, including age, sex, New York Heart Association class, ejection fraction, blood pressure, and medications.
We chose these particular prediction models because they have been extensively validated. The HIV model's internal validity has been demonstrated by the agreement of predicted and observed times with treatment failure and survival in the 3545 patient sample on which it was calibrated. Its external validity has been demonstrated by the agreement of predicted and observed mortality rates in a sample of 12 574 patients who were almost entirely distinct from the derivation cohort, 19 as well as its ability to predict the rate of accumulating highly active antiretroviral therapy resistance mutations 20 and the U-shaped relationship between antiretroviral adherenceandresistanceaccumulation. 21 PatientswithHIVwerestratified by CD4 lymphocyte count and viral load. The Seattle Heart Failure Model's validity has been demonstrated by accurately predicting survival in 5 separate cohorts that were distinct from the derivationcohort,totaling9942patientswithheartfailureand17 307 person-years of follow-up. 22 Patients with heart failure were stratified by their particular score, ranging from −1 (the most favorable score) to ϩ4 (the worst score). (The model is available online free of charge at www.SeattleHeartFailureModel.org).
Interpreting the payoff time requires estimating life expectancy, whereas some predictive models may instead estimate median survival or the probability of survival over a designated time horizon (eg, the Seattle Heart Failure Model). In these circumstances, the DEALE can be used to estimate life expectancy from alternate survival metrics. 18 Accordingly, we used the DEALE to estimate life expectancy from the Seattle Heart Failure Model's survival predictions for those stratifications with sufficiently high predicted mortality (Ͼ10% per year).
RESULTS
We first estimated the payoff times for colorectal cancer screening for our 2 target groups (50-year-old men with HIV and 60-year-old women with CHF). We then estimated the life expectancy for each group, stratifying these estimates based on important prognostic indicators. By comparing their life expectancies with our estimates of the payoff times, we were able to determine whether colorectal cancer screening should be advised for these groups.
ESTIMATING PAYOFF TIMES
For 50-year-old men, the mortality payoff time was 1.9 years. As of that point in time, the mortality decrease from benefits of colorectal cancer screening started to outweigh the mortality increase from harms of screening ( Figure 1A) . The adverse event payoff time was 5.0 years; as of that point in time, the reduction in adverse events from benefits of colorectal cancer screening started to outweigh the increase in adverse events from harms of screening ( Figure 1B) . The increased colon cancer risk of 60-year-old women compared with 50-year-old men resulted in greater potential benefits from colorectal cancer screening and therefore in earlier payoff times. The mortality payoff time was 0.7 years (Figure 2A) , and the adverse event payoff time was 2.9 years ( Figure 2B ).
ESTIMATING LIFE EXPECTANCY
Based on the survival model of Braithwaite and colleagues, 50-year-old men with HIV may be grouped into 9 separate risk strata according to pretreatment viral load and CD4 lymphocyte count ( Table 1) . Individuals in these strata have life expectancies ranging from 12.5 years (highest viral load, lowest CD4 lymphocyte count) to 24.0 years (lowest viral load, highest CD4 lymphocyte count). Based on the Seattle Heart Failure Model, patients with CHF may be grouped into 6 separate risk strata ( Table 2) . The 3 most favorable risk strata (−1, 0, and 1) have estimated life expectancies of greater than 5 years, whereas the 3 least favorable strata (2, 3, and 4) have estimated life expectancies of 4.0, 1.4, and 0.6 years, respectively.
COMPARING PAYOFF TIMES WITH LIFE EXPECTANCY
The life expectancies of 50-year-old men with HIV (12.5-24.0 years) exceed the payoff times for colorectal cancer screening,regardlessofriskstratumandregardlessofwhether thepayofftimereflectedmortality(1.9years)oradverseevents (5.0 years). Correspondingly, colorectal cancer screening may be favorable for 50-year-old men with HIV. The life expectancies of 60-year-old women with CHF (0.6 toϾ5 years) do not always exceed the payoff times for colorectal cancer screening; therefore, colorectal cancer screening is likely to be unfavorable for some of these patients. In particular, women in risk strata 3 and 4 have shorter life expectancies (1.4 and 0.6 years, respectively) than one or both payoff times (0.7 and 2.9 years, respectively).
COMMENT
We developed a framework for individualizing guidelines based on comorbidity. This framework is designed "from the ground up" to be compatible with clinical decision aids becauseitquantitativelyweighsguidelines'benefitsandharms and therefore can offer clear guidance for decision making.
It is substantially different from other published approaches forindividualizingguidelines,whichrequirequalitativevaluations that are often complex and are less likely to be applicable at the point of care. [1] [2] [3] [4] [5] The recent development of comorbidity-basedprognosticmodelsthataresimple 6 orhave user-friendly Web-based interfaces 22 has greatly facilitated the development of this framework. Although some clinicians may wonder why any decision rule is necessary, when it is theoretically possible to recalculate risks and benefits each time a guideline is applied, it would be prohibitively difficult (if not impossible) to iterate all possible combinations of guidelines and comorbidities and to perform a distinct, evidence-based analysis for each combination.
Our approach estimates the time until a guideline's incremental benefits are likely to exceed its incremental harms and then asks whether this time is longer than a patient's comorbidity-adjusted life expectancy. In our illustration of the payoff time framework, we found that individuals with HIV are likely to benefit from screening because of the relatively long life expectancy conferred by current therapies. In contrast, individuals with severe CHF may be unlikely to benefit from colorectal cancer screening because of their relatively short life expectancies.
An important strength of our framework is its potential to affect health policy. Because the payoff time provides an objective method of inferring when a guideline may confer harm rather than benefit, it may be used to delineate circumstances when guideline compliance should not count toward quality benchmarks or toward pay for performance. For example, we would argue that if a clinician elects not to screen for colorectal cancer in a 60-year-old woman with risk strata 3 or 4 CHF, it should not harm the clinician's quality "report card" or "performance" portfolio.
The concept of a payoff time is likely to be intuitive, as expert panels sometimes specify a minimum life expectancy that is a prerequisite for a guideline's expected benefits to exceed its expected harms. For example, the US Preventive Services Task Force advocates waiving colorectal cancer screening when a patient's estimated life expectancy is less than 5 years. These recommendations can be thought of as payoff times that are estimated by expert opinion rather than the more databased approach of our framework.
An important limitation of our work is that we did not consider harm and benefit data particular to the comorbidities under consideration. For example, CHF is likely to increase the harm from colorectal cancer screening by increasing susceptibility to harm from complications, and our payoff time calculations did not consider this likely impact. However, it is important to note that using data that are not comorbidity specific is not an intrinsic limitation of the payoff time approach, but rather a limitation of the data sources that were available. Once data concerning the interaction between CHF and harm from colonoscopy are available, the information may be incorporated into the payoff time estimation. Furthermore, even when comorbidity-specific data are unavailable, payoff time inferences may still be valid if the comorbidity is likely to result in an underestimate of the payoff time. For example, CHF is likely to result in an underestimation of the colorectal cancer screening payoff time because it is likely to increase the chance of harm (eg, an increase in complication rate) more than it is likely to increase the chance of benefit. We may therefore infer that patients with risk strata 3 or 4 CHF should not undergo colorectal cancer screening because their life expectancies are lower than the underestimates (and would therefore also be lower than the true payoff times).
Our framework has other limitations. It does not consider patient preferences, which are an important consideration in any clinical decision. Indeed, it is important to emphasize that the payoff time should not be interpreted as a clinical dictum, but rather as a clinical decision support tool, one among many information sources in a shared decision between patient and clinician. Another limitation of our approach is that it does not consider costs. However, it would be straightforward to consider costs for any particular willingness to pay threshold (eg, $100 000 per life-year saved) by determining when a guideline first confers the corresponding life expectancy benefit. As more stringent willingness-to-pay criteria are specified, the associated payoff times would lengthen.
In conclusion, we present a practical framework for tailoring clinical guidelines to comorbid populations that may be applied at the point of care. This method has the potential to reduce morbidity and mortality, while decreasing use of resources, and therefore has implications for health policy and clinical care. June 18, 2007. 
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